• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU
Click for more information
4.26% 4.5¢

IMUGENE LIMITED - Announcements

Market Cap $386.7M  ! watchlist Created with Sketch. Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMU Investor Presentation26/03/19
IMU IMU Pre-IND FDA Meeting Provides Guidance for KEY-VaxxPRICE SENSITIVE20/03/19
IMU Imugene doses first patient in HER-Vaxx phase 2 trialPRICE SENSITIVE14/03/19
IMU IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACRPRICE SENSITIVE04/03/19
IMU Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
IMU Pause in TradingPRICE SENSITIVE28/02/19
IMU Imugene Announces Presentation on HER-Vaxx at the AACR 2019PRICE SENSITIVE28/02/19
IMU Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data26/02/19
IMU Appendix 4C - Quarterly and Business UpdatePRICE SENSITIVE30/01/19
IMU Investor PresentationPRICE SENSITIVE10/01/19
IMU IMU appoints distinguished scientist to the Company SAB07/01/19
IMU Change of Director's Interest Notice - PH20/12/18
IMU IMU Meets Endpoints in Phase 1b Gastric Cancer TrialPRICE SENSITIVE17/12/18
IMU Change of Director's Interest Notice - LC21/11/18
IMU Appendix 3B and 708A Notice21/11/18
IMU Change of Director's Interest Notice - PH21/11/18
IMU Results of Meeting13/11/18
IMU AGM Presentation13/11/18
IMU Imugene Advances to Phase 2 in Gastric Cancer TrialPRICE SENSITIVE13/11/18
IMU Imugene Receives $1.85 million R&D Tax IncentivePRICE SENSITIVE09/11/18
IMU Appendix 4C - quarterlyPRICE SENSITIVE30/10/18
IMU Change of Director's Interest Notice - AH22/10/18
IMU Appendix 3B (Exercise of Options) and 708A Notice22/10/18
IMU Notice of Annual General Meeting/Proxy Form09/10/18
IMU Change in Executive Remuneration08/10/18
IMU ESMO President joins Imugene Scientific Advisory Board04/10/18
IMU Imugene appoints leading cancer researcher to SAB01/10/18
IMU Appendix 4G28/09/18
IMU Annual Report to shareholders28/09/18
IMU Imugene commences cGMP manufacture of PD-1 cancer vaccinePRICE SENSITIVE21/09/18
IMU Imugene appoints gastrointestinal cancer expert to SAB18/09/18
IMU Imugene Completes Phase 1b Cancer Vaccine Trial RecruitmentPRICE SENSITIVE11/09/18
IMU Appendix 4E and Audited Financial ReportPRICE SENSITIVE31/08/18
IMU Imugene appoints Dr Mark Marino Chief Medical Officer23/08/18
IMU Appendix 4C - Quarterly and Business UpdatePRICE SENSITIVE31/07/18
IMU 2018 Bioshares Presentation27/07/18 download Created with Sketch. 5.08MB
IMU Change of Director's Interest Notice - LC24/07/18 download Created with Sketch. 36.75KB
IMU Change of Director's Interest Notice - PH24/07/18 download Created with Sketch. 36.89KB
IMU PD-1 cancer vaccine development updatePRICE SENSITIVE23/07/18 download Created with Sketch. 399.17KB
IMU Change of Director's Interest Notice - PH20/07/18 download Created with Sketch. 36.89KB
IMU Appendix 3B ESOP20/07/18 download Created with Sketch. 102.77KB
IMU Appendix 3B16/07/18 download Created with Sketch. 101.77KB
IMU Change of Director's Interest Notice - CW12/07/18 download Created with Sketch. 37.13KB
IMU Change of Director's Interest Notice - LC12/07/18 download Created with Sketch. 37.03KB
IMU Change of Director's Interest Notice - PH12/07/18 download Created with Sketch. 37.12KB
IMU Appendix 3B and 708A Notice12/07/18 download Created with Sketch. 1.47MB
IMU Becoming a substantial holder10/07/18 download Created with Sketch. 106.53KB
IMU Results of Meeting09/07/18 download Created with Sketch. 852.18KB
IMU General Meeting Presentation09/07/18 download Created with Sketch. 1MB
IMU Rights Issue Results & Shortfall Notification06/07/18 download Created with Sketch. 541.1KB
IMU Appendix 3B (Exercise of Options) and 708A Notice14/06/18 download Created with Sketch. 923.74KB
IMU Response to ASX QueryPRICE SENSITIVE08/06/18 download Created with Sketch. 496.2KB
IMU Notice of General Meeting/Proxy Form07/06/18 download Created with Sketch. 1.17MB
IMU Imugene Entitlement Offer notice to option holders07/06/18 download Created with Sketch. 304.3KB
IMU Imugene Entitlement Offer notice to ineligible shareholders07/06/18 download Created with Sketch. 303.46KB
IMU Imugene Entitlement Offer notice to eligible shareholders07/06/18 download Created with Sketch. 308KB
IMU Appendix 3B07/06/18 download Created with Sketch. 785.24KB
IMU ProspectusPRICE SENSITIVE07/06/18 download Created with Sketch. 976.05KB
IMU Capital Raising Presentation07/06/18 download Created with Sketch. 1.6MB
IMU IMUGENE RAISES $20.1 MILLIONPRICE SENSITIVE07/06/18 download Created with Sketch. 584.16KB
IMU Imugene Licences Extensive B-Cell Immuno-Oncology PortfolioPRICE SENSITIVE07/06/18 download Created with Sketch. 341.69KB
IMU Trading HaltPRICE SENSITIVE05/06/18 download Created with Sketch. 443.43KB
IMU Appendix 4C - quarterlyPRICE SENSITIVE26/04/18
IMU Ceasing to be a substantial holder from PTM13/04/18
IMU Initial Director's Interest Notice - LC29/03/18
IMU Leslie Chong Appointed as Managing DirectorPRICE SENSITIVE28/03/18
IMU Change in substantial holding13/03/18
IMU Change in substantial holding13/03/18
IMU Half Yearly Report and AccountsPRICE SENSITIVE27/02/18
IMU Arginine Modulator Active in Cancer ModelsPRICE SENSITIVE19/02/18
IMU Novel Anti-PD-1 Mimotope Vaccine Ready for DevelopmentPRICE SENSITIVE12/02/18
IMU IMU Meets Investigator for Gastric Cancer Clinical TrialPRICE SENSITIVE09/02/18
IMU Cancer vaccine shows early promise in clinical trialPRICE SENSITIVE07/02/18
IMU Change in substantial holding06/02/18
IMU Change in substantial holding06/02/18
IMU Business Update - December Quarter Appendix 4CPRICE SENSITIVE29/01/18
IMU SF Biotech Presentation09/01/18
IMU Change of Director's Interest Notice - CW28/12/17
IMU Appendix 3B22/12/17
IMU Rights Issue Results & Shortfall NotificationPRICE SENSITIVE19/12/17
IMU Change of Director's Interest Notice - CW13/12/17
IMU Change of Director's Interest Notice - PH12/12/17
IMU Section 708A Notice11/12/17
IMU Change of Director's Interest Notice11/12/17
IMU Appendix 3B and Required LR 3.10.5A Information06/12/17
IMU Appendix 3B05/12/17
IMU International Cancer Specialist Joins Imugene SAB04/12/17
IMU Imugene Entitlement Offer notice to option holders23/11/17
IMU Imugene Entitlement Offer notice to ineligible shareholders23/11/17
IMU Imugene Entitlement Offer notice to eligible shareholders23/11/17
IMU Appendix 3B23/11/17
IMU CAPITAL RAISING PRESENTATION23/11/17
IMU ProspectusPRICE SENSITIVE23/11/17
IMU IMUGENE RAISES $8.7 MILLIONPRICE SENSITIVE23/11/17
IMU Trading HaltPRICE SENSITIVE21/11/17
IMU Expert Briefing Presentation14/11/17
IMU Results of Meeting14/11/17
IMU AGM Presentation14/11/17
IMU Appendix 4C - Quarterly and Business UpdatePRICE SENSITIVE27/10/17
IMU Change in substantial holding26/10/17
IMU Investor Presentation
26/03/19
IMU IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
20/03/19PRICE SENSITIVE
IMU Imugene doses first patient in HER-Vaxx phase 2 trial
14/03/19PRICE SENSITIVE
IMU IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
04/03/19PRICE SENSITIVE
IMU Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
IMU Pause in Trading
28/02/19PRICE SENSITIVE
IMU Imugene Announces Presentation on HER-Vaxx at the AACR 2019
28/02/19PRICE SENSITIVE
IMU Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data
26/02/19
IMU Appendix 4C - Quarterly and Business Update
30/01/19PRICE SENSITIVE
IMU Investor Presentation
10/01/19PRICE SENSITIVE
IMU IMU appoints distinguished scientist to the Company SAB
07/01/19
IMU Change of Director's Interest Notice - PH
20/12/18
IMU IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
17/12/18PRICE SENSITIVE
IMU Change of Director's Interest Notice - LC
21/11/18
IMU Appendix 3B and 708A Notice
21/11/18
IMU Change of Director's Interest Notice - PH
21/11/18
IMU Results of Meeting
13/11/18
IMU AGM Presentation
13/11/18
IMU Imugene Advances to Phase 2 in Gastric Cancer Trial
13/11/18PRICE SENSITIVE
IMU Imugene Receives $1.85 million R&D Tax Incentive
09/11/18PRICE SENSITIVE
IMU Appendix 4C - quarterly
30/10/18PRICE SENSITIVE
IMU Change of Director's Interest Notice - AH
22/10/18
IMU Appendix 3B (Exercise of Options) and 708A Notice
22/10/18
IMU Notice of Annual General Meeting/Proxy Form
09/10/18
IMU Change in Executive Remuneration
08/10/18
IMU ESMO President joins Imugene Scientific Advisory Board
04/10/18
IMU Imugene appoints leading cancer researcher to SAB
01/10/18
IMU Appendix 4G
28/09/18
IMU Annual Report to shareholders
28/09/18
IMU Imugene commences cGMP manufacture of PD-1 cancer vaccine
21/09/18PRICE SENSITIVE
IMU Imugene appoints gastrointestinal cancer expert to SAB
18/09/18
IMU Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
11/09/18PRICE SENSITIVE
IMU Appendix 4E and Audited Financial Report
31/08/18PRICE SENSITIVE
IMU Imugene appoints Dr Mark Marino Chief Medical Officer
23/08/18
IMU Appendix 4C - Quarterly and Business Update
31/07/18PRICE SENSITIVE
IMU 2018 Bioshares Presentation
27/07/18 download Created with Sketch. 5.08MB
IMU Change of Director's Interest Notice - LC
24/07/18 download Created with Sketch. 36.75KB
IMU Change of Director's Interest Notice - PH
24/07/18 download Created with Sketch. 36.89KB
IMU PD-1 cancer vaccine development update
23/07/18PRICE SENSITIVE download Created with Sketch. 399.17KB
IMU Change of Director's Interest Notice - PH
20/07/18 download Created with Sketch. 36.89KB
IMU Appendix 3B ESOP
20/07/18 download Created with Sketch. 102.77KB
IMU Appendix 3B
16/07/18 download Created with Sketch. 101.77KB
IMU Change of Director's Interest Notice - CW
12/07/18 download Created with Sketch. 37.13KB
IMU Change of Director's Interest Notice - LC
12/07/18 download Created with Sketch. 37.03KB
IMU Change of Director's Interest Notice - PH
12/07/18 download Created with Sketch. 37.12KB
IMU Appendix 3B and 708A Notice
12/07/18 download Created with Sketch. 1.47MB
IMU Becoming a substantial holder
10/07/18 download Created with Sketch. 106.53KB
IMU Results of Meeting
09/07/18 download Created with Sketch. 852.18KB
IMU General Meeting Presentation
09/07/18 download Created with Sketch. 1MB
IMU Rights Issue Results & Shortfall Notification
06/07/18 download Created with Sketch. 541.1KB
IMU Appendix 3B (Exercise of Options) and 708A Notice
14/06/18 download Created with Sketch. 923.74KB
IMU Response to ASX Query
08/06/18PRICE SENSITIVE download Created with Sketch. 496.2KB
IMU Notice of General Meeting/Proxy Form
07/06/18 download Created with Sketch. 1.17MB
IMU Imugene Entitlement Offer notice to option holders
07/06/18 download Created with Sketch. 304.3KB
IMU Imugene Entitlement Offer notice to ineligible shareholders
07/06/18 download Created with Sketch. 303.46KB
IMU Imugene Entitlement Offer notice to eligible shareholders
07/06/18 download Created with Sketch. 308KB
IMU Appendix 3B
07/06/18 download Created with Sketch. 785.24KB
IMU Prospectus
07/06/18PRICE SENSITIVE download Created with Sketch. 976.05KB
IMU Capital Raising Presentation
07/06/18 download Created with Sketch. 1.6MB
IMU IMUGENE RAISES $20.1 MILLION
07/06/18PRICE SENSITIVE download Created with Sketch. 584.16KB
IMU Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
07/06/18PRICE SENSITIVE download Created with Sketch. 341.69KB
IMU Trading Halt
05/06/18PRICE SENSITIVE download Created with Sketch. 443.43KB
IMU Appendix 4C - quarterly
26/04/18PRICE SENSITIVE
IMU Ceasing to be a substantial holder from PTM
13/04/18
IMU Initial Director's Interest Notice - LC
29/03/18
IMU Leslie Chong Appointed as Managing Director
28/03/18PRICE SENSITIVE
IMU Change in substantial holding
13/03/18
IMU Change in substantial holding
13/03/18
IMU Half Yearly Report and Accounts
27/02/18PRICE SENSITIVE
IMU Arginine Modulator Active in Cancer Models
19/02/18PRICE SENSITIVE
IMU Novel Anti-PD-1 Mimotope Vaccine Ready for Development
12/02/18PRICE SENSITIVE
IMU IMU Meets Investigator for Gastric Cancer Clinical Trial
09/02/18PRICE SENSITIVE
IMU Cancer vaccine shows early promise in clinical trial
07/02/18PRICE SENSITIVE
IMU Change in substantial holding
06/02/18
IMU Change in substantial holding
06/02/18
IMU Business Update - December Quarter Appendix 4C
29/01/18PRICE SENSITIVE
IMU SF Biotech Presentation
09/01/18
IMU Change of Director's Interest Notice - CW
28/12/17
IMU Appendix 3B
22/12/17
IMU Rights Issue Results & Shortfall Notification
19/12/17PRICE SENSITIVE
IMU Change of Director's Interest Notice - CW
13/12/17
IMU Change of Director's Interest Notice - PH
12/12/17
IMU Section 708A Notice
11/12/17
IMU Change of Director's Interest Notice
11/12/17
IMU Appendix 3B and Required LR 3.10.5A Information
06/12/17
IMU Appendix 3B
05/12/17
IMU International Cancer Specialist Joins Imugene SAB
04/12/17
IMU Imugene Entitlement Offer notice to option holders
23/11/17
IMU Imugene Entitlement Offer notice to ineligible shareholders
23/11/17
IMU Imugene Entitlement Offer notice to eligible shareholders
23/11/17
IMU Appendix 3B
23/11/17
IMU CAPITAL RAISING PRESENTATION
23/11/17
IMU Prospectus
23/11/17PRICE SENSITIVE
IMU IMUGENE RAISES $8.7 MILLION
23/11/17PRICE SENSITIVE
IMU Trading Halt
21/11/17PRICE SENSITIVE
IMU Expert Briefing Presentation
14/11/17
IMU Results of Meeting
14/11/17
IMU AGM Presentation
14/11/17
IMU Appendix 4C - Quarterly and Business Update
27/10/17PRICE SENSITIVE
IMU Change in substantial holding
26/10/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
4.5¢ 		Change
-0.002(4.26%) 		Mkt cap ! $386.7M
Open High Low Value Volume
4.7¢ 4.8¢ 4.4¢ $890.8K 19.42M

Buyers (Bids)

No. Vol. Price($)
2 176601 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 969572 8
View Market Depth
Last trade - 16.10pm 06/11/2024 (20 minute delay) ?
Last
4.5¢ 		  Change
-0.002 ( 2.81 %)
Open High Low Volume
4.8¢ 4.8¢ 4.5¢ 9435451
Last updated 15.59pm 06/11/2024 ?
IMU (ASX) Chart

Top Stories

Bitcoin jumps 8% to beat record on Trump vote optimism

Bitcoin has been a big winner on financial markets today, tracking Donald Trump's election highs with an 8% rise and beating a previous record
Palladium's the newest geopolitical hot commodity. But ASX exposure is limited On October 24, the USA reportedly approached its G7 counterparts and proposed a ban on Russian titanium, and, palladium.
Nanocap Si6 Metals to kick off drilling at Monument gold project WA, chasing past hits Nanocap Si6 Metals (ASX:SI6) is on the cusp of kicking off drilling at its Monument project in WA, sniffing after historical gold hit targets.
Lord picks up high-grade copper play in Western Australia, with past intercepts of up to 6.62% Lor Resources Ltd has entered into a binding earn-in agreement with Blackrock Resources Pty Ltd to take on up to 80% of the Ilgarari project
The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint Let’s get straight to the point: of all the smallcaps in the Telecommunications index, The Market Ltd could be one of the most overlooked.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.